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Abstract
Although infections contribute to growth faltering in preschool children, malaria prevention seems to have limited impact
on height status. In 2002–2003, a malaria intermittent preventive treatment (IPT) trial was conducted in Senegal, including
randomly selected preschool children from 11 villages. A rapid decrease in stunting prevalence (from 28.3 to 16.3%; P ,
0.0001) was reported in both intervention and placebo groups. During this 15-mo period, both groups of children benefited
from active detection and prompt treatment of malaria attacks. In this study, we investigated whether management of
malaria morbidity could explain the improvement of height status. An anthropometric survey, conducted in September
2004 in the area, included 929 2- to 5-y-old children. Some 539 children, previously included in the 2002–2003 IPT trial,
benefited from active malaria morbidity management and formed the malaria trial group. The remaining 390 children
constituted the control group. Mean height-for-age and stunting prevalence in September 2004 were compared between
groups adjusting for age and mother’s activity. Mean height-for-age Z-scores did not differ between trial (21.17 6 0.93)
and control children (21.24 6 1.00; P = 0.25). Only 36- to 47-mo-old malaria trial children had a lower prevalence of
stunting than controls of similar age (19.4 vs. 28.7%; P = 0.044). Compared with the usually slow progression of height
status related to better living conditions, it seems very likely that the rapid improvement observed among IPT study
children resulted from the trial. These findings suggest that improved health services provided by the trial may also have
benefited children not included living in study villages. J. Nutr. 140: 625–629, 2010.
Introduction
Stunting remains highly prevalent in developing countries and
affects 38% of children under 5 y of age in sub-Saharan Africa
(1). Growth faltering is known to be a major cause of impaired
cognitive development, decreased school performance, and, later,
reduced physical work capacity and reproductive outcome (2).
Among multiple risk factors associated with stunting, infec-
tions strongly participate in growth faltering. Indeed, acute and
chronic infections may affect linear growth by decreasing food
intake and nutrient absorption and increasing metabolic re-
quirements (3). Numerous studies have investigated the impact
of malaria prevention on childhood nutritional status. It has
been widely demonstrated that malaria prevention improves the
weight gain of children living in malaria endemic areas (4–7);
however, few trials have shown a significant effect on linear
growth (8,9).
In 2002, a randomized, double-blind, placebo-controlled
intervention study of seasonal intermittent preventive treatment
(IPT)5 of malaria was conducted in a cohort of 2- to 59-mo-old
children living in a rural area of Senegal where transmission is
mainly seasonal. The intervention was highly successful; the risk
of a clinical attack was reduced by 86% (10). The prevalence of
wasting increased significantly in the control group during the
transmission season but remained constant in intervention
children (11). In addition, an unexpected 42% decrease in
stunting was observed in both groups during follow-up: from
28.3% (95% CI: 25.6–31.0) at inclusion to 16.3% (95% CI:
13.9–18.7) 15 mo later at the end of the intervention (P ,
0.0001). The main hypothesis to explain this result was that this
dramatic decrease did not result from the intervention per se (in
that case, it would have benefited the intervention group only)
but rather from malaria morbidity management provided to all
children during the study. Indeed, all children included in this
trial benefited from active weekly malaria case detection and
prompt treatment during 2 consecutive transmission seasons.
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To test this hypothesis, a cross-sectional anthropometric
survey conducted in September 2004 allowed for the compar-
ison of height-for-age of children who had taken part in the
2002–03 IPT study to that of a control group of children who
had not participated in any interventions. These 2 groups were
comparable due to random selection of IPT study children
within the 11 study villages. We hypothesized that children who
had benefited from malaria morbidity management would
display a better height status (higher mean height-for-age and
lower prevalence of stunting) compared with children who had
not received such health care.
Materials and Methods
Study area and population. The study was conducted in an area close
to Niakhar, a rural district of Senegal located 150 km from the capital
city Dakar. The area contains 30 villages within 230 km2. Since 1983,
a demographic surveillance system has been operating in the area and
dates of birth and death are knownwith accuracy for all inhabitants. The
mortality rate for children aged 1–4 y was 144 per 1000 live births from
1994 to 1999 (12) and malaria accounted for one-fourth of all deaths in
this age group (13). Plasmodium falciparummalaria transmission occurs
from August to October and preschool death rates increase sharply at
that time of the year (12,14).
The nutritional status of infants and preschool children also
varies widely by season. Body weight is highest in the dry season
(April–May) and lowest at the end of the rainy season (October–
November) (12).
2002–2003 IPT trial. A randomized, double-blind, placebo-controlled,
intermittent preventive antimalarial treatment trial was conducted in
2002 and 2003 in this area. Details on this intervention have been pro-
vided previously (10). In brief, in 2002, an IPT trial included 1088 chil-
dren aged 2–59mo in September 2002 randomly selectedwithin 11 villages
in the area (10). Then, each child was randomly assigned to the treated
group or placebo group. Artesunate and sulfadoxine-pyrimethamine
(SP) or matching placebo were given monthly 3 times at the height of the
rainy season during the first year of the trial (from mid-September to
mid-November). During the 2003 transmission season, an observational
follow-up study evaluated the potential rebound effect of the interven-
tion, i.e. the risk of a higher clinical attack rate in former intervention
children. Thus, no chemoprevention was provided during the follow-up,
but all children included in this trial benefited fromweekly active malaria
case detection from July to December (through home visits by medical
staff). Children ill with malaria received prompt treatment: in 2002,
chloroquine as first-line treatment and SP or quinine as second-line
treatment, and in 2003 SP as first-line treatment and quinine as second-
line treatment. At all times, injectable quinine was administered in case
of persistent vomiting or severe malaria. In 2002, children received an
antimalaria treatment immediately after a malaria attack was confirmed
biologically (parasitaemia . 3000 parasites/mL), whereas in 2003, all
children with symptoms evocative of malaria attack were treated prior
to parasitological confirmation. Furthermore, passive surveillance was
operating at 2 dispensaries in the area; in addition to the nurse in-
charge, a physician was appointed by the research project for the
investigation of all children who presented with symptoms evocative of
malaria. Treatment was identical to that of cases identified through
active surveillance. There was no evidence of any rebound effect in 2003;
indeed, former intervention children did not have higher rates of clinical
attacks compared with placebo children [incidence ratio: 0.98 (0.82;
1.17)] (10).
During the study, 4 anthropometric surveys were conducted (Sep-
tember and November 2002, July and December 2003) (11).
2004 IPT trial. An additional trial was conducted from September 2004
to December 2004 in 14 villages, including the 11 villages involved in the
2002–2003 IPT trial (15). This trial included a total of 2020 children
aged from 6 to 59 mo who were randomly allocated to 4 different IPT
regimens. A baseline survey was conducted at inclusion in September
2004 for the collection of anthropometric data.
Study design. The present study was set up as a comparison of height-
for-age and stunting in September 2004 between children exposed and
those not exposed to health interventions (active malaria attack
detection and prompt treatment) within the 2002–03 malaria prevention
trial.
Participants. Criteria for inclusion in the present analysis were age
between 26 and 59 mo in September 2004 and residence in 1 of the
11 villages included in the 2002–03 IPT trial. Exclusion criteria consisted
of refusal to participate and the presence of a detectable handicap that
might alter linear growth.
Among the 2020 children aged 6–59 mo enrolled in the intervention
in September 2004, 1452 lived in the 11 IPT villages. Among them, 539
children (aged 26–59 mo) had previously been included in the 2002–
2003 IPT trial and were included in the malaria trial group. Among the
913 remaining children, 390 were aged 26–59 mo in September 2004
(i.e. aged from 2 to 36 mo in September 2002) and were included in the
control group. The parents of 38 children, randomly selected from the
database to take part in the 2002–3003 trial, refused participation.
However, for this analysis, they were kept in the malaria trial group to
maintain comparability of groups (intent-to-include analysis).
Oral, witnessed, informed consent of parents was sought at home
visits prior to anthropometric assessment.
Data collection. In September 2004, anthropometric data were
collected in 2 health centers by well-trained and experienced measurers
in accordance with internationally recommended procedures (16).
Weight was measured using an electronic scale to the nearest 10 g
(SECA). Standing height of children was measured using locally made
wooden boards precise to the nearest millimeter. Height measurements
were taken twice and the mean used for the analysis. Anthropometric
data from IPT 2002/2003 and 2004 were collected in the same manner
by the same 2 anthropometrists. Sociodemographic data (the child’s date
of birth, village of residence, and maternal occupation and education)
were taken from the Niakhar study area database.
Statistical analysis. The nutritional indicators height-for-age, weight-
for-height, and weight-for-age were computed in Z-scores of the WHO
2006 child growth standards (17) using SAS software version 8.2.
Stunting, wasting, and underweight were defined for values , 22 for
height-for-age Z-scores (HAZ), weight-for-height Z-scores (WHZ), and
weight-for-age Z-scores (WAZ), respectively.
Sociodemographic and anthropometric characteristics were com-
pared between the malaria trial and control groups using t tests for
quantitative variables and chi-square tests for qualitative variables.
Mean HAZ was compared between malaria trial and control groups
using a general linear model. Comparison of stunting prevalence
between the 2 groups was performed using a multiple logistic regression
and corresponding odds ratio was estimated. Analyses were conducted
with adjustment for variables that tended to be associated with study
group (P , 0.20).
To test whether height status varied with age within each study
group, ANOVA and logistic regressions were used for HAZ and
stunting, respectively. Interaction between study group and age group
was tested for both models to test whether child age was an effect
modifier in the relationship between study group and height status.
Finally, analyses stratified on age were performed usingMantel-Haenszel
test and t tests for the mean (PROCMULTTEST, SAS V8.2) for stunting
prevalence and mean HAZ, respectively.
Values in the text related to the nutritional indicators are means6 SD
and those related to stunting, wasting, underweight, and sociodemo-
graphic characteristics are percent. All differences were considered
significant at P , 0.05.
Ethics. The study protocol was approved by the ethical review
committees of the Senegalese Ministry of Health and the Institut de
Recherche pour le De´veloppement.
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Results
Children included in the malaria trial group and those included
in the control group did not differ in terms of village of residence
(data not shown), sex, or maternal characteristics (Table 1).
However, the 2 groups differed significantly by age group.
Indeed, children included in the malaria trial group were slightly
older than those included in the control group (Table 1).
When adjusting for age and mother’s activity in a multivar-
iate analysis, mean HAZ did not differ between malaria trial and
control children (b =20.07;P = 0.25; Table 1). Similar results were
found for prevalence of stunting [odds ratiomalaria trial vs. control =
1.28; 95% CI (0.92; 1.79); P = 0.14].
Neither mean WHZ nor mean WAZ differed significantly
between groups and prevalence of malnutrition was similar as
well (Table 1).
Addition of an interaction term between age and study groups
(malaria trial vs. control) in the multivariate models allowed for
testing whether the impact of malaria morbidity management
differed according to age. Interaction terms between intervention
group and age were not significant for either mean HAZ (P =
0.18) or the prevalence of stunting (P = 0.25).
Mean HAZ and stunting prevalence differed with age within
the control group (P = 0.01): the highest mean HAZ values and
lowest stunting prevalence were found in the oldest age group
(48–59.9 mo) (Table 2). No differences with age were noted in
the malaria trial group.
In age-specific subanalyses, mean HAZ tended to be higher in
the malaria trial group compared with the control group among 36- to 47.9-mo-old children only (P = 0.08; Table 2), whereas
the prevalence of stunting was lower in this age group for
malaria trial children compared with control children (P =
0.044; Table 2).
Discussion
In this study, we sought to determine whether malaria morbidity
management might be an explanation for the impressive 42%
decrease in prevalence of stunting (from 28.3 to 16.3%)
observed in both placebo and malaria-preventively treated
children at the end of the 2002–2003 IPT study (11). Indeed,
all children included in this study benefited from weekly active
malaria case detection by home visits and prompt treatment.
Children who have benefited from active malaria management
morbidity during the IPT intervention were compared with
control children living in the same villages who did not receive
such health care.
We found no significant difference in height status (mean
HAZ or stunting prevalence) between children who had
benefited from active malaria morbidity management during
the IPT intervention (the malaria trial group) and control
children, according to our preplanned global analysis. Thus, our
hypothesis of a role of active malaria morbidity management for
explaining the improvement in height status of IPT children was
not confirmed by this analysis. However, in post-hoc, age-
specific subanalyses, malaria trial children aged 36–47.9 mo had
a lower prevalence of stunting than controls of same age (19.4
vs. 28.9%; P = 0.044).
The major limitation of our study is the lack of information
concerning baseline nutritional status of control children. The
2002–2003 IPT study was based entirely on a comparison
between children benefitting from malaria prevention treatment
and placebo children. Therefore, the present study relies on the
assumption that the 2 groups had similar nutritional status at
baseline; i.e. at the beginning of the 2002-IPT study. This seems
TABLE 1 Sociodemographic and anthropometric
characteristics of the 2002–2003 malaria trial
and control groups 9 mo after the trial’s end
(September 2004)1
Characteristics n
Malaria trial
group n
Control
group P 2
Total 539 390
Child's age, mo
24–35.9 156 28.9 144 36.9
36–47.9 196 36.4 135 34.6 0.03
48–59.9 187 34.7 111 28.5
Sex 0.63
Female 276 51.2 206 52.8
Male 263 48.8 184 47.2
Maternal characteristics
Mother's instruction3 99 18.4 73 18.7 0.89
Mother's activity4 66 12.2 64 16.4 0.07
Nutritional status
HAZ 539 21.17 6 0.93 390 21.24 6 1.00 0.255
WHZ 539 20.34 6 1.04 390 20.32 6 0.97 0.755
WAZ 539 20.91 6 0.92 390 20.93 6 0.90 0.685
Prevalence of malnutrition
Stunting 96 17.8 84 21.5 0.146
Wasting 31 5.8 19 4.9 0.586
Underweight 58 11.0 43 10.8 0.786
1 Values are means 6 SD or %.
2 P-value for between-group comparisons.
3 Percent of mothers who ever attended primary school.
4 Percent of mothers with a professional activity.
5 Comparison between groups was done using a general linear model adjusted for age
groups and mother’s activity.
6 Comparison between groups was done using a logistic regression adjusted for age
groups and mother’s activity.
TABLE 2 HAZ and stunting prevalence in children in the malaria
trial and control groups by age1
n
Malaria trial
children n
Control
children P 2 P
Total 539 390
HAZ
Child age, mo 0.293
24–35.9 148 21.15 6 0.96 152 21.24 6 0.95 0.41
36–47.9 183 21.22 6 0.94 148 21.42 6 1.09 0.08
48–59.9 170 21.14 6 0.90 148 21.04 6 0.95 0.38
P 4 0.61 0.01
Stunting prevalence
Child age, mo 0.175
24–35.9 148 17.3 152 20.1 0.53
36–47.9 183 19.4 148 28.9 0.044
48–59.9 170 16.6 148 14.4 0.62
P 4 0.76 0.02
1 Values are mean 6 SD or %.
2 P-value for comparison between malaria trial children and control children for each
stratum of age using t tests and chi-square tests, respectively.
3 P-value for comparison between malaria trial and control children, using t test for the
mean stratified on age groups.
4 P-value for comparison among age groups.
5 P-value for comparison between malaria trial and control children, with stratification
on age group using the Mantel-Haenszel test.
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plausible, because the 2002-IPT intervention was conducted
among a randomly selected group of children within the 11
study villages (10). To respect randomization, 38 children whose
parents had refused participation in the malaria trial and who
had thus not benefitted from active malaria surveillance and
treatment were maintained in the intervention group for this
analysis. However, excluding them from the study or including
them in the control group did not change the results (data not
shown).
Thus, our findings showed very limited differences in the
prevalence of stunting between malaria trial and control groups
in September 2004. Therefore, we hypothesize that the control
group has experienced an important decrease in stunting from
2002 to 2004 almost similar to that of to the malaria trial group.
The significantly lower stunting prevalence in malaria trial
children aged 36–47.9 mo in September 2004 compared with
controls of same age might be a chance finding. On the other
hand, these children were aged 12–23.9 mo at the initiation of
malaria surveillance and treatment in 2002 and linear growth is
most sensitive to environmental insults in younger children
(18,19). However, the apparent lack of impact of participation
in the IPT trial on linear growth of children aged below 12 mo
in 2002 is surprising given the malaria incidence rate was not
lower among infants (10).
We have compared our results to data of mean HAZ in
central Senegal and Fatick (the region in which the Niakhar
study area is located) provided by the Senegalese Demographic
and Health Surveys (DHS) and the Multiple Indicators Cluster
Surveys. These data indicate that the mean HAZ of preschool
children increased from 21.56 6 1.69 in 1992 (DHS-II 1992/
1993) to 21.35 6 1.79) in 2000 (Multiple Indicators Cluster
Surveys-II-2000), and 21.01 6 1.30 in 2005 (DHS-IV, 2005).
These increases were highly significant (P = 0.008 and P = 0.004
for the 2 periods, respectively).
Thus, a marked increase in height status of preschool children
occurred in the region between 2000 and 2005 and also in the
country globally (data not shown). This improvement of height
status was probably related to better socioeconomic conditions.
Indeed, data from the World Bank showed an increase in gross
national income per capita from 510 U.S. dollars in 2000 to 750
U.S. dollars in 2006 (20,21). Thus, an improvement of living
conditions in the Niakhar area might partly explain the decrease
in stunting observed among preschool children during the IPT
intervention.
Among recent economic changes in the study area, one might
cite improved techniques of cattle raising (i.e. cross-breeding
between the traditional hampered ox and cattle imported from
Europe; Amady Ndiaye-Sarr, personal communication).
Specific nutrition programs for 6- to 35-mo-old children and
pregnant women have been carried out in Senegal, first in urban
and thereafter also in rural areas, and might theoretically have
contributed to this reduction of malnutrition. However, they do
not seem to have had any impact on stunting prevalence
compared with control areas (22). Furthermore, these programs
have never been operating in the Niakhar area (Abdoulaye Ka,
personal communication).
For 2003, we have data for 12- to 59-mo-old children only.
With regards to change in mean HAZ or stunting prevalence
from 1984 [based on the original data of a study by Garenne
et al. (23)] to 2009 among 12- to 59-mo-old children living in the
11 study villages (Table 3), the impressive increase in mean HAZ
during the IPT trial occurred very rapidly over a 15-mo period.
Moreover, the comparison of mean HAZ of 12- to 59-mo-old
children between 2004 and 2009 suggested that children’s
height status worsened during this 5-y period (P = 0.03) and that
the improvement in height status from 2002 to 2003 was a
temporary phenomenon.
Improvement of height status associated with better socio-
economic conditions has been described as a slow and regular
process spanning several years (24–26). Therefore, the secular
trend or the overall improvement of living conditions in the area
suggested by data of the DHS may have contributed to the
decrease in stunting prevalence observed between September
2002 and December 2003 in IPT children. However, it is
unlikely to entirely explain this dramatic decrease. Other
mechanisms must be involved. The implementation of the IPT
intervention seems to be the most likely cause. Our hypothesis is
that although they did not benefit from active malaria detection,
control children benefited from several medical services imple-
mented in the villages during the trial, notably through treat-
ment free of charge by well-qualified physicians present at
dispensaries 7 d/wk for malaria attacks and other diseases as
well. In addition, long-term presence of health workers and
medical doctors in the villages during rounds for active malaria
surveillance may have promoted better health care for the
population as a whole and in particular for children. This
phenomenon has been described previously (27).
Because the IPT trial provided general health and medical
services not focusing on malaria morbidity only, the intervention
could also result in mothers’ awareness of their children’s health.
Consequently, changes in mothers’ behavior associated with
better health facilities free of charge might have improved the
general morbidity management in study villages and contributed
to this important decrease in the prevalence of stunting.
Although the IPT trial appeared to be the most likely
explanation for the improvement of height status of the children
living in study villages, it might theoretically also result from a
chance finding.
In conclusion, the results of this study did not confirm our
study hypothesis of a specific role of active malaria morbidity
TABLE 3 Change in HAZ and stunting prevalence of 12- to 59-mo-old children living in the 11 study
villages using the WHO 2006 international growth standard1
1984 2002 2003 2004 2009
n 1274 864 688 1299 1297
HAZ2 21.49 6 1.2 21.54 6 1.1 21.15 6 1.00 21.22 6 1.05 21.31 6 1.07
P 3 0.32 , 0.0001 0.14 0.03
Stunting (HAZ ,22) 31.2 31.4 18.8 20.1 24.7
P 4 0.96 , 0.0001 0.51 0.006
1 Values are means 6 SD or %.
2 Computed from the original data of the study conducted by Garenne et al. (23).
3 Mean HAZ comparison between two consecutive studies using t tests.
4 Stunting prevalence comparison between two consecutive studies using chi-square tests.
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management for the improvement of height status in IPT-
included children. However, medical services, improved health
facilities, and the long-term presence of health workers and
medical doctors in the villages during the IPT trial seem the most
likely causes of the rapid decrease in stunting prevalence
observed during the 15-mo period of the IPT trial. These
findings suggest that health services associated with the
implementation of the IPT study have benefited both included
and nonincluded children in study villages.
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